Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.

Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK.

Cancer Res. 2017 Jul 1;77(13):3455-3466. doi: 10.1158/0008-5472.CAN-16-3240. Epub 2017 May 16.

2.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

3.

Cooperative Dynamics of AR and ER Activity in Breast Cancer.

D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.

Mol Cancer Res. 2016 Nov;14(11):1054-1067. Epub 2016 Aug 26.

4.

A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK.

Cancer Res. 2015 Nov 1;75(21):4651-64. doi: 10.1158/0008-5472.CAN-15-2011. Epub 2015 Sep 11.

5.

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.

Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK.

Horm Cancer. 2015 Dec;6(5-6):206-13. doi: 10.1007/s12672-015-0232-3. Epub 2015 Jul 23. Review.

PMID:
26201402
6.

Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.

Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK.

Mol Cancer Ther. 2015 Mar;14(3):769-78. doi: 10.1158/1535-7163.MCT-14-0926. Epub 2015 Feb 23.

7.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

8.

MicroRNA regulation of epithelial plasticity in cancer.

D'Amato NC, Howe EN, Richer JK.

Cancer Lett. 2013 Nov 28;341(1):46-55. doi: 10.1016/j.canlet.2012.11.054. Epub 2012 Dec 8. Review.

PMID:
23228634
9.

Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.

D'Amato NC, Ostrander JH, Bowie ML, Sistrunk C, Borowsky A, Cardiff RD, Bell K, Young LJ, Simin K, Bachelder RE, Delrow J, Dawson A, Yee LD, Mrózek K, Clay TM, Osada T, Seewaldt VL.

PLoS One. 2012;7(9):e45684. doi: 10.1371/journal.pone.0045684. Epub 2012 Sep 25.

10.

CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3.

11.

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.

Supplemental Content

Loading ...
Support Center